Advertisement

Topics

Autifony Therapeutics Company Profile

16:42 EST 10th December 2018 | BioPortfolio

Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK's Neuroscience Centre of Excellence for Drug Discovery.

The company is privately funded by leading venture capital investors. Autifony’s head office is at the Imperial College Incubator in London, and it has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy. The company works closely with hearing research experts at University College London’s Ear Institute, Yale University, and other academic collaborators around the world to progress its pioneering research.

Autifony Science

Autifony’s approach to hearing loss is to target particular ion channels, known as Kv3 voltage gated potassium channels, which play a key role at many levels of the central auditory pathway. Studies conducted by Prof Len Kaczmarek’s group at Yale University suggest that Autifony’s Kv3 modulators may help to restore the timing of firing of neurons in the auditory brainstem important for central auditory processing.

For Age Related Hearing Loss

In age-related hearing loss, there is evidence for an age-related decline in expression of Kv3 channels. The reduction of these channels and the corresponding loss of function of certain auditory neurons may contribute to the reduction in hearing acuity and difficulty that patients experience in understanding speech. Autifony’s drug is designed to modulate Kv3 channels, improve hearing acuity, and thus reduce some of the symptoms of age-related hearing loss, in particular difficulty with speech understanding. Studies in preclinical models conducted by Autifony’s academic collaborators at the Institute of Experimental Medicine in Prague (led by Prof Josef Syka) show that Autifony’s drugs can improve key aspects of hearing acuity in aged animals.

For Tinnitus

Several hypotheses exist to explain how alterations in central auditory processing might lead to the emergence of phantom sounds.  Experimental studies have confirmed that tinnitus is associated with changes in neural activity at multiple levels of the auditory pathway, including many brain areas in which Kv3 channels are found. Profiling of our lead compound shows it can modulate function in both brainstem and cortex in ways that could be beneficial in the treatment of tinnitus. Our research with academic collaborators at UCL’s Ear Institute (led by Dr Jennifer Linden) and at the University of Southern Illinois (led by Dr Jeremy Turner) shows that Autifony’s drugs can reduce both the behavioural and electrophysiological correlates of tinnitus in preclinical models.

For Noise Induced Hearing Loss

Acute or chronic noise can damage the cochlea, initiating a series of adaptive as well as maladaptive changes within central auditory pathways that contribute to the perceived hearing loss and sometimes the emergence of tinnitus. In collaborative studies with the University of Leicester (led by Dr Martine Hamann) we have shown that one of the changes in the central nervous system following noise is the reduced function of Kv3 channels in the auditory brainstem (Pilati et al. 2012, Hearing Research 283:98-106). Further studies in preclinical models with the University of Southern Illinois (led by Prof Kathy Campbell) suggest that Autifony’s drugs can protect against hearing loss induced by loud noise.

Source: http://www.autifony.com/autifony-science.asp

Location

Imperial College Incubator
Level 1 Bessemer Building, Imperial College
London
SW7 2AZ
United Kingdom

Contact

Email: info@autifony.com


News Articles [689 Associated News Articles listed on BioPortfolio]

Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain

Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making...  

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this we...

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CE...

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop d...

Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As thi...

iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

PubMed Articles [457 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Safety, Blood Levels and Effects of AUT00206

The study medicine is a potential future treatment for schizophrenia, an illness that affects the way that people think, feel or behave. It is not clear what causes schizophrenia, but it's...

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1282 Associated Companies listed on BioPortfolio]

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious ...

More Information about "Autifony Therapeutics" on BioPortfolio

We have published hundreds of Autifony Therapeutics news stories on BioPortfolio along with dozens of Autifony Therapeutics Clinical Trials and PubMed Articles about Autifony Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Autifony Therapeutics Companies in our database. You can also find out about relevant Autifony Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record